Editas Accounts Payable from 2010 to 2025

EDIT Stock  USD 1.30  0.09  6.47%   
Editas Medicine Accounts Payable yearly trend continues to be comparatively stable with very little volatility. Accounts Payable will likely drop to about 5.4 M in 2025. Accounts Payable is the amount Editas Medicine owes to suppliers or vendors for products or services received but not yet paid for. It represents Editas Medicine's short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2013-12-31
Previous Quarter
12.5 M
Current Value
5.5 M
Quarterly Volatility
3.2 M
 
Yuan Drop
 
Covid
Check Editas Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Editas Medicine's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Interest Expense of 3 M or Selling General Administrative of 59.8 M, as well as many indicators such as Price To Sales Ratio of 3.07, Dividend Yield of 0.0 or PTB Ratio of 0.61. Editas financial statements analysis is a perfect complement when working with Editas Medicine Valuation or Volatility modules.
  
Check out the analysis of Editas Medicine Correlation against competitors.
For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

Latest Editas Medicine's Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Editas Medicine over the last few years. An accounting item on the balance sheet that represents Editas Medicine obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Editas Medicine are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Editas Medicine's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Editas Medicine's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Editas Accounts Payable Regression Statistics

Arithmetic Mean4,097,245
Geometric Mean2,593,377
Coefficient Of Variation70.64
Mean Deviation2,383,590
Median5,050,000
Standard Deviation2,894,455
Sample Variance8.4T
Range9.1M
R-Value0.86
Mean Square Error2.3T
R-Squared0.75
Significance0.000017
Slope524,787
Total Sum of Squares125.7T

Editas Accounts Payable History

20255.4 M
20245.5 M
20238.3 M
20229.5 M
2021M
20206.4 M
20195.8 M

About Editas Medicine Financial Statements

Editas Medicine shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Editas Medicine investors may analyze each financial statement separately, they are all interrelated. The changes in Editas Medicine's assets and liabilities, for example, are also reflected in the revenues and expenses on on Editas Medicine's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Accounts Payable5.5 M5.4 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Editas Stock Analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.